Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that Kenneth A. Berlin, President and Chief Executive Officer of Advaxis, will participate in the Benzinga Biotech Small Cap Conference to be held March 24-25, 2021
PRINCETON, N.J., March 23, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc., (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that Kenneth A. Berlin, President and Chief Executive Officer of Advaxis, will participate in the Benzinga Biotech Small Cap Conference to be held March 24-25, 2021. Mr. Berlin will present on March 24th, 2021 at 2:30 pm ET.
Investors can view the presentation and request a 1x1 meeting once they register for the conference here.
Tune in to the YouTube link on Day 1 Track 1 at 2:30 pm ET for the presentation: https://www.youtube.com/watch?v=BOoOknbYO2c
About Advaxis, Inc.
Advaxis, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Lm-based antigen delivery products. These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-based strains are believed to be a significant advancement in immunotherapy as they integrate multiple functions into a single immunotherapy and are designed to access and direct antigen presenting cells to stimulate anti-tumor T cell immunity, activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable T cells to eliminate tumors.
To learn more about Advaxis, visit www.advaxis.com and connect on Twitter, LinkedIn, Facebook and YouTube.
Investor Contact
Tim McCarthy
LifeSci Advisors, LLC
Tim@lifesciadvisors.com
(212) 915-2564
